rs116700257
Variant summary
Our verdict is Benign. Variant got -9 ACMG points: 0P and 9B. BP4_StrongBP6BS2
The NM_004646.4(NPHS1):c.3562G>A(p.Ala1188Thr) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000297 in 1,613,560 control chromosomes in the GnomAD database, including 3 homozygotes. In-silico tool predicts a benign outcome for this variant. 16/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_004646.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -9 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
NPHS1 | NM_004646.4 | c.3562G>A | p.Ala1188Thr | missense_variant | 28/29 | ENST00000378910.10 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
NPHS1 | ENST00000378910.10 | c.3562G>A | p.Ala1188Thr | missense_variant | 28/29 | 1 | NM_004646.4 | P2 | |
NPHS1 | ENST00000353632.6 | c.3442G>A | p.Ala1148Thr | missense_variant | 27/28 | 5 | A2 |
Frequencies
GnomAD3 genomes AF: 0.00158 AC: 240AN: 152210Hom.: 2 Cov.: 32
GnomAD3 exomes AF: 0.000390 AC: 98AN: 251474Hom.: 0 AF XY: 0.000258 AC XY: 35AN XY: 135916
GnomAD4 exome AF: 0.000164 AC: 240AN: 1461232Hom.: 1 Cov.: 31 AF XY: 0.000128 AC XY: 93AN XY: 726998
GnomAD4 genome AF: 0.00158 AC: 240AN: 152328Hom.: 2 Cov.: 32 AF XY: 0.00154 AC XY: 115AN XY: 74482
ClinVar
Submissions by phenotype
not provided Uncertain:1Benign:2
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 28, 2024 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Athena Diagnostics | Jul 10, 2018 | - - |
Likely benign, criteria provided, single submitter | clinical testing | GeneDx | Oct 08, 2020 | This variant is associated with the following publications: (PMID: 28117080) - |
Finnish congenital nephrotic syndrome Benign:2
Benign, criteria provided, single submitter | clinical testing | Vasylyeva lab, Texas Tech University Health Sciences Center | Oct 06, 2017 | - - |
Benign, criteria provided, single submitter | clinical testing | Counsyl | Oct 06, 2017 | - - |
not specified Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jul 07, 2022 | Variant summary: NPHS1 c.3562G>A (p.Ala1188Thr) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.00042 in 252492 control chromosomes (gnomAD and Bonomo_2014), predominantly at a frequency of 0.0058 within the African or African-American subpopulation in the gnomAD database. The observed variant frequency within African or African-American control individuals in the gnomAD database is approximately 2-fold of the estimated maximal expected allele frequency for a pathogenic variant in NPHS1 causing Nephrotic Syndrome, Type 1 phenotype (0.0034), suggesting that the variant is a benign polymorphism found primarily in populations of African or African-American origin. c.3562G>A has been reported in the literature in at least one heterozygous individual affected with Nephrotic Syndrome, without strong evidence for causality (e.g. Bierzynska_2017) and therefore this report does not provide unequivocal conclusions about association of the variant with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Four clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. Three laboratories classified the variant as benign (n=1)/likely benign (n=2), and one classified it as VUS. Based on the evidence outlined above, the variant was classified as likely benign. - |
NPHS1-related disorder Benign:1
Likely benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Oct 27, 2020 | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at